Anhui Jiexi Pharmaceutical Co., Ltd.

Primary study objective: To investigate the bioequivalence of minocycline hydrochloride capsules (specification: 100 mg (calculated as C23H27N3O7)) developed by Anhui Jiexi Pharmaceutical Co., Ltd. and minocycline hydrochloride capsules (trade name: MINOMYCIN ®, specification: 100 mg (calculated as C23H27N3O7)) certified by Pfizer Japan Inc. after a single oral administration in healthy Chinese subjects. Secondary study objective: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Primary study objective: To investigate the bioequivalence of minocycline hydrochloride capsules (specification: 100 mg (calculated as C23H27N3O7)) developed by Anhui Jiexi Pharmaceutical Co., Ltd. and minocycline hydrochloride capsules (trade name: MINOMYCIN ®, specification: 100 mg (calculated as C23H27N3O7)) certified by Pfizer Japan Inc. in healthy Chinese subjects after single oral administration on an empty stomach. Secondary study objective: To observe the safety of the test preparation and the reference preparation in healthy Chinese subjects.

Main purpose: The pioglitazone and metformin tablets produced by Huayi Pharmaceutical Technology (Anhui) Co., Ltd. entrusted by Anhui Jiexi Pharmaceutical Co., Ltd. were used as the test preparation (specification: 15mg/500mg). According to the relevant regulations of bioequivalence testing, it was compared with Takeda Tuopin Co., Ltd. The company's pioglitazone and metformin tablets (trade name: Miguro Tablets LD, specifications: 15mg/500mg) are used as reference preparations. Bioequivalence tests are conducted to compare the efficacy of single administration of the two preparations under fasting and postprandial conditions. Bioequivalence. Secondary purpose: To evaluate the safety of a single oral dose of the test preparation (Pioglitazone and Metformin Tablets, T) and the reference preparation (Pioglitazone and Metformin Tablets, LD, R) in healthy Chinese adult subjects.